Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment

Fig. 1

Complete and partial responses are frequently observed in metastases treated with concurrent SRS and pembrolizumab on first follow-up MRI. Waterfall plot showing percentage change in size of melanoma brain metastasis maximum diameter after SRS and the indicated systemic therapy at first follow-up MRI. (CR, complete response; PR, partial response; Stab, stable disease; PD, progressive disease; pembro, pembrolizumab; ipi, ipilimumab; SRS, stereotactic radiosurgery)

Back to article page